Upfront boost to gross disease followed by elective pelvic radiation improves compliance to radiation therapy delivery metrics in locally advanced vulvar cancer

M. Chadha, T. Shao, M. Lit, V. Gupta, K. Zakashansky, K. Zeligs, V. Kolev

Research output: Contribution to journalArticlepeer-review

Abstract

Locally advanced cancer of the vulva (LACV) is commonly diagnosed in older women (>65 years), and is treated using combined multimodality therapy (CMT) that includes radiation therapy (RT). Compliance to optimal RT metrics, including completion of > 20 fractions, overall treatment duration of < 8 weeks (56 days), and < 1 week intra-treatment break is associated with better disease outcomes. However, published results note that a significant number of patients with LACV do not adhere to these metrics. The aim of our study is to evaluate whether a modified sequence of RT delivery, treating the localized boost volume upfront followed by the larger elective nodal volume is associated with improved compliance to optimal RT delivery metrics.

Original languageEnglish
Article number101362
JournalGynecologic Oncology Reports
Volume52
DOIs
StatePublished - Apr 2024

Keywords

  • Chemotherapy
  • Combined modality therapy
  • Locally advanced cancer of the vulva
  • Overall treatment time
  • Radiation therapy

Fingerprint

Dive into the research topics of 'Upfront boost to gross disease followed by elective pelvic radiation improves compliance to radiation therapy delivery metrics in locally advanced vulvar cancer'. Together they form a unique fingerprint.

Cite this